http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
a Worldwide Yearly Survey of New Data in Adverse Drug Reactions
Provides clinicians and medical investigators with a survey of new data and trends in the area of adverse drug reactions and interactions.
Front Cover; Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions; Copyright; Contributors; Contents; Preface; Special Reviews in SEDA 38; Table of Essays, Annuals 1-37; Abbreviations; ADRs, ADEs and SEDs: A Bird's Eye View; Introduction; Analysis of ADEs, ADRs, Side Effects and Toxicity; Terminology; EIDOS; DoTS; WHO Classification; References on Adverse Drug Reactions; Pharmacogenomic Considerations; Introduction; Definition of Pharmacogenomics; References on Pharmacogenomic Considerations; Immunological Reactions
Type I Reactions (IgE-Mediated Anaphylaxis Immediate Hypersensitivity); Type II Reactions (Cytotoxic Reactions); Type III Reactions (Immune Complex Reactions); Type IV Reactions (Cell-Mediated or Delayed Hypersensitivity Reactions); Other Types of Reactions; References; Analysis of Toxicological Reactions; Potentiation Reactions; Synergistic Effect; Additive Effect; Antagonistic Effects; References; Grades of Adverse Drug Reactions; References; FDA Pregnancy Categories/Classification of Teratogenicity; References; Conclusion
Chapter 1: Central Nervous System Stimulants and Drugs That Suppress Appetite Amphetamine and Amphetamine Derivates [SEDA-34, 1; SEDA-35, 1; SEDA 36, 1; SEDA 37, 1]; Studies; Ecstasy (3,4-Methylenedioxy-N-Methylamphetamine; MDMA); Studies; Methylphenidate [SEDA-34, 5; SEDA-35, 1; SEDA-36, 1; SEDA-37, 1]; Studies; Methylxanthines; Caffeine [SEDA-15, 588; SEDA-32, 14; SEDA-33, 11; SEDA-34, 6; SEDA-36, 1; SEDA-37, 1]; Studies; Selective Norepinephrine Reuptake Inhibitors Atomoxetine [SEDA-34, 4; SEDA-36, 1; SEDA-37, 1]; Studies; Vigilance Promoting Drugs
Modafinil and Armodafinil [SEDA-34, 6 SEDA-36, 1; SEDA-37, 1]; Studies; Drugs That Suppress Appetite [SEDA-34, 8; SEDA-36, 1; SEDA-37, 1]; Lorcaserin [SEDA-37, 1]; Phentermine [SEDA-34, 8; SEDA-36, 1; SEDA-37, 1]; Phentermine/Topiramate Extended Release (XR) [SEDA-37, 1]; Studies; Parasympathomimetics [SEDA-34, 9; SEDA-36, 1; SEDA-37, 1]; Rivastigmine [SEDA-34, 10; SEDA-36, 1; SEDA-37, 1]; Studies; Donepezil [SEDA-34, 10; SEDA-36, 1; SEDA-37, 1]; Studies; Galantamine [SEDA-36, 1; SEDA-37, 1]; Studies; References; Chapter 2: Antidepressant Drugs; General; Hematological
Gastrointestinal Bleeding Intracranial Hemorrhage; Postpartum Hemorrhage; Reproductive System (Pregnancy, Development and Infancy); Spontaneous Abortion/Miscarriage; Teratogenesis-Cardiac Malformations; Persistent Pulmonary Hypertension of the Newborn (PPHN); Autism; Bone Density, Fracture Risk and Falls; Suicide/Self-Harm; Stroke; Selective Serotonin Re-Uptake Inhibitors (SSRIs) [SED-15, 3109; SEDA-31, 18; SEDA-32, 33; SEDA-33, 26; SEDA-34, 17; SEDA-35 ... ; Citalopram and Escitalopram; Dystonia; Serotonin and Noradrenaline Re-Uptake Inhibitors (SNRIS); Venlafaxine and Desvenlafaxine [SED-15, 3614.
Includes bibliographical references at the end of each chapters and indexes.
Drug-Related Side Effects and Adverse Reactions
Side Effects of Drugs Annual ; Volume 38
Side Effects of Drugs Annual : A Worldwide Yearly Survey of New Data in Adverse Drug Reactions